Why in the News?
At the 78th World Health Assembly held in Geneva, the World Health Organisation (WHO) adopted a new Pandemic Agreement that aims to make the global response to future pandemics more equitable and effective.
About the WHO Pandemic Agreement:
- Adoption: It was unanimously adopted at the 78th World Health Assembly in Geneva after 3 years of negotiation since the COVID-19 pandemic.
- Legal Basis: It was adopted under Article 19 of the WHO Constitution, making it only the second such legally binding agreement after the WHO Framework Convention on Tobacco Control (2003).
- Primary Goal: To ensure fair and timely access to vaccines, medicines, and diagnostic tools during future pandemics.
- Stakeholders: It promotes collaboration among countries, WHO, pharmaceutical firms, civil society, and other stakeholders.
- Next Steps: It will come into force once ratified by at least 60 countries; the final annex is expected by May 2026.
- Irritant: The US has not joined, raising concerns about the agreement’s global effectiveness.
Key Highlights of the Agreement:
- Pathogen Access and Benefit Sharing (PABS): A new system will ensure quick virus sample sharing with companies, who must give 20% of vaccines and medicines to WHO—10% as donations and 10% at affordable prices.
- Global Supply Chain and Logistics Network (GSCL): A WHO-managed network will ensure emergency access to critical supplies during pandemics.
- Coordinating Financial Mechanism: A funding system will support countries in pandemic preparedness and response.
- Sustainable Local Production: Countries are encouraged to build vaccine and medicine production capacity to ensure rapid and equal access.
- Technology and Knowledge Transfer: Supports technology sharing with developing nations using licensing, financing, and regulatory tools, coordinated via WHO-managed hubs.
- Pandemic Prevention and Surveillance: Countries must improve early detection, routine vaccinations, and address lab safety, antimicrobial resistance, and zoonotic threats.
- Respect for Sovereignty: The WHO will not enforce national policies like lockdowns, vaccine mandates, or travel bans; countries retain full control over responses.
| [UPSC 2022] In the context of vaccines manufactured to prevent COVID-19 pandemic, consider the following statements:
1. The Serum Institute of India produced COVID-19 vaccine named Covishield using mRNA platform. 2. Sputnik V vaccine is manufactured using vector-based platform. 3. COVAXIN is an inactivated pathogen-based vaccine. Which of the statements given above are correct? Options: (a) 1 and 2 only (b) 2 and 3 only* (c) 1 and 3 only (d) 1, 2 and 3 |
Get an IAS/IPS ranker as your 1: 1 personal mentor for UPSC 2024
